Andrew Walding
AstraZeneca (United Kingdom) · 42 works · 1,592 citations · h-index 15
Top works
- 136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial
- Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset
- 354TiP A phase III randomised open-label study of extended adjuvant therapy with camizestrant vs standard endocrine therapy (ET) in patients with ER+/HER2– early breast cancer (BC) and an intermediate or high risk of recurrence (CAMBRIA-1)
- Monomethylfumarate affects polarization of monocyte‐derived dendritic cells resulting in down‐regulated Th1 lymphocyte responses
- Neoadjuvant Osimertinib With/Without Chemotherapy Versus Chemotherapy Alone for EGFR -Mutated Resectable Non-Small-Cell Lung Cancer: NeoADAURA
- Human peripheral blood mononuclear cells express GABAA receptor subunits
- Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
- Cardiac Safety of Osimertinib: A Review of Data
- Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer
- Activation of E-prostanoid4and E-prostanoid2receptors inhibits TNF-α release from human alveolar macrophages
- Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial
- Differential gene expression analysis in human monocyte-derived macrophages: Impact of cigarette smoke on host defence
- Large‐scale isolation of human skeletal muscle satellite cells from post‐mortem tissue and development of quantitative assays to evaluate modulators of myogenesis
- Correlation of gene and mediator expression with clinical endpoints in an acute interleukin-1β-driven model of joint pathology
- Discovery of isoindoline and tetrahydroisoquinoline derivatives as potent, selective PPARδ agonists
- Patient Experience of Symptoms and Side Effects when Treated with Osimertinib for Advanced Non-Small-Cell Lung Cancer: A Qualitative Interview Substudy
- Patient-reported symptoms possibly related to treatment with osimertinib or chemotherapy for advanced non-small cell lung cancer
- SERENA-4: A phase 3 comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive, HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease.
- P03.02 Neoadjuvant Osimertinib with/without Chemotherapy vs Chemotherapy for EGFR Mutated Resectable NSCLC: NeoADAURA
- Time to deterioration of patient-reported outcomes in non-small cell lung cancer: exploring different definitions